Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19"
Drugs
.
2020 Sep;80(14):1501-1503.
doi: 10.1007/s40265-020-01396-8.
Authors
John G Rizk
1
,
Kamyar Kalantar-Zadeh
2
3
4
,
Mandeep R Mehra
5
,
Carl J Lavie
6
,
Youssef Rizk
7
,
Donald N Forthal
8
9
Affiliations
1
Edson College, Arizona State University, Phoenix, AZ, USA. john.rizk@lau.edu.
2
Division of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, School of Medicine, Irvine, CA, USA.
3
Department of Epidemiology, University of California, Los Angeles, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
4
Tibor Rubin VA Long Beach Healthcare System, Long Beach, CA, USA.
5
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
6
John Ochsner Heart and Vascular Institute, Ochsner Clinical School-the University of Queensland School of Medicine, New Orleans, LA, USA.
7
Department of Family Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
8
Division of Infectious Diseases, Department of Medicine, University of California, Irvine, School of Medicine, Irvine, CA, USA.
9
Department of Molecular Biology and Biochemistry, University of California, Irvine, School of Medicine, Irvine, CA, USA.
PMID:
32880806
PMCID:
PMC7471515
DOI:
10.1007/s40265-020-01396-8
No abstract available
Publication types
Letter
Comment
MeSH terms
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections* / drug therapy
Humans
Immunomodulation
Pandemics*
Pneumonia, Viral*
SARS-CoV-2